These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

563 related articles for article (PubMed ID: 15699107)

  • 21. Mutation of the invariant chain transmembrane region inhibits II degradation, prolongs association with MHC class II, and selectively disrupts antigen presentation.
    Frauwirth K; Shastri N
    Cell Immunol; 2001 May; 209(2):97-108. PubMed ID: 11446742
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Presentation of antigens internalized through the B cell receptor requires newly synthesized MHC class II molecules.
    Forquet F; Barois N; Machy P; Trucy J; Zimmermann VS; Leserman L; Davoust J
    J Immunol; 1999 Mar; 162(6):3408-16. PubMed ID: 10092796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Processing and presentation of HLA class I and II epitopes by dendritic cells after transfection with in vitro-transcribed MUC1 RNA.
    Dörfel D; Appel S; Grünebach F; Weck MM; Müller MR; Heine A; Brossart P
    Blood; 2005 Apr; 105(8):3199-205. PubMed ID: 15618468
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Asparagine endopeptidase is not essential for class II MHC antigen presentation but is required for processing of cathepsin L in mice.
    Maehr R; Hang HC; Mintern JD; Kim YM; Cuvillier A; Nishimura M; Yamada K; Shirahama-Noda K; Hara-Nishimura I; Ploegh HL
    J Immunol; 2005 Jun; 174(11):7066-74. PubMed ID: 15905550
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early endosomes and a late endocytic compartment generate different peptide-class II MHC complexes via distinct processing mechanisms.
    Griffin JP; Chu R; Harding CV
    J Immunol; 1997 Feb; 158(4):1523-32. PubMed ID: 9029086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Presentation by recycling MHC class II molecules of an influenza hemagglutinin-derived epitope that is revealed in the early endosome by acidification.
    Sinnathamby G; Eisenlohr LC
    J Immunol; 2003 Apr; 170(7):3504-13. PubMed ID: 12646611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficient presentation of both cytosolic and endogenous transmembrane protein antigens on MHC class II is dependent on cytoplasmic proteolysis.
    Mukherjee P; Dani A; Bhatia S; Singh N; Rudensky AY; George A; Bal V; Mayor S; Rath S
    J Immunol; 2001 Sep; 167(5):2632-41. PubMed ID: 11509605
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficient internalization of MHC class II-invariant chain complexes is not sufficient for invariant chain proteolysis and class II antigen presentation.
    Swier K; Miller J
    J Immunol; 1995 Jul; 155(2):630-43. PubMed ID: 7608541
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Superior tumor protection induced by a cellular vaccine carrying a tumor-specific T helper epitope by genetic exchange of the class II-associated invariant chain peptide.
    van Bergen J; Camps M; Offringa R; Melief CJ; Ossendorp F; Koning F
    Cancer Res; 2000 Nov; 60(22):6427-33. PubMed ID: 11103809
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modulation of antigen presentation and class II expression by a class II-associated invariant chain peptide.
    Zechel MA; Chaturvedi P; Lee-Chan EC; Rider BJ; Singh B
    J Immunol; 1996 Jun; 156(11):4232-9. PubMed ID: 8666792
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cancer immunotherapy by antisense suppression of Ii protein in MHC-class-II-positive tumor cells.
    Qiu G; Goodchild J; Humphreys RE; Xu M
    Cancer Immunol Immunother; 1999 Dec; 48(9):499-506. PubMed ID: 10602887
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Suppression of major histocompatibility complex class II-associated invariant chain enhances the potency of an HIV gp120 DNA vaccine.
    Lu X; Wu S; Blackwell CE; Humphreys RE; von Hofe E; Xu M
    Immunology; 2007 Feb; 120(2):207-16. PubMed ID: 17116173
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A role for cathepsin L and cathepsin S in peptide generation for MHC class II presentation.
    Hsieh CS; deRoos P; Honey K; Beers C; Rudensky AY
    J Immunol; 2002 Mar; 168(6):2618-25. PubMed ID: 11884425
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Invariant chain alters the malignant phenotype of MHC class II+ tumor cells.
    Clements VK; Baskar S; Armstrong TD; Ostrand-Rosenberg S
    J Immunol; 1992 Oct; 149(7):2391-6. PubMed ID: 1527384
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MHC class II-associated invariant chain peptide replacement by T cell epitopes: engineered invariant chain as a vehicle for directed and enhanced MHC class II antigen processing and presentation.
    Malcherek G; Wirblich C; Willcox N; Rammensee HG; Trowsdale J; Melms A
    Eur J Immunol; 1998 May; 28(5):1524-33. PubMed ID: 9603457
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Class II-restricted presentation of a hen egg lysozyme determinant derived from endogenous antigen sequestered in the cytoplasm or endoplasmic reticulum of the antigen presenting cells.
    Brooks AG; McCluskey J
    J Immunol; 1993 May; 150(9):3690-7. PubMed ID: 8473726
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Deletion of a C-terminal sequence of the class II-associated invariant chain abrogates invariant chains oligomer formation and class II antigen presentation.
    Bertolino P; Staschewski M; Trescol-Biémont MC; Freisewinkel IM; Schenck K; Chrétien I; Forquet F; Gerlier D; Rabourdin-Combe C; Koch N
    J Immunol; 1995 Jun; 154(11):5620-9. PubMed ID: 7751615
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T cell recognition of major histocompatibility complex class II complexes with invariant chain processing intermediates.
    Morkowski S; Goldrath AW; Eastman S; Ramachandra L; Freed DC; Whiteley P; Rudensky AYu
    J Exp Med; 1995 Nov; 182(5):1403-13. PubMed ID: 7595211
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biosynthesis of major histocompatibility complex molecules and generation of T cells in Ii TAP1 double-mutant mice.
    Tourne S; van Santen HM; van Roon M; Berns A; Benoist C; Mathis D; Ploegh H
    Proc Natl Acad Sci U S A; 1996 Feb; 93(4):1464-9. PubMed ID: 8643655
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Class II-restricted presentation of an endogenously derived immunodominant T-cell determinant of hen egg lysozyme.
    Brooks A; Hartley S; Kjer-Nielsen L; Perera J; Goodnow CC; Basten A; McCluskey J
    Proc Natl Acad Sci U S A; 1991 Apr; 88(8):3290-4. PubMed ID: 1707537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.